Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 10/20 | 0.38 |
| ▸ | KRAS | P01116 | 6/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT2 | P31751 | 1/20 | 0.35 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14480930 | 1.00 | PIK3CD (0.39) | PIK3CDSOS1KRASCYP1A2CYP2D6 | |
| SCHEMBL14481337 | 0.93 | PIK3CD (0.38) | PIK3CDSOS1KRASPIK3R2CD274 | |
| SCHEMBL15900051 | 0.93 | PIK3CD (0.38) | PIK3CDSOS1KRASPIK3R2CD274 | |
| SCHEMBL14480692 | 0.92 | CYP3A4 (0.38) | PIK3CDSOS1KRASPIK3R2CD274 | |
| SCHEMBL14480691 | 0.92 | CYP3A4 (0.38) | PIK3CDSOS1KRASPIK3R2CD274 | |
| SCHEMBL14480910 | 0.92 | PIK3CD (0.37) | PIK3CDKRASPIK3R2CD274AKT1 | |
| SCHEMBL14480909 | 0.92 | PIK3CD (0.37) | PIK3CDKRASPIK3R2CD274AKT1 | |
| SCHEMBL14481197 | 0.91 | SOS1 (0.40) | PIK3CDSOS1KCNH2PIK3R2CD274 | |
| SCHEMBL15899853 | 0.90 | PIK3CD (0.39) | PIK3CDSOS1PIK3R2CD274AKT1 | |
| SCHEMBL14481018 | 0.88 | TNF (0.38) | PIK3CDSOS1PIK3R2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | claimed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | claimed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | claimed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | PIK3CD 13/4885SOS1 2164/4885KRAS 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.